Concepedia

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

Edward Z. Song, Xin Wang, Benjamin Philipson, Qian Zhang, Radhika Thokala, Logan Zhang, Charles‐Antoine Assenmacher, Zev A. Binder, Guo‐li Ming, Donald M. O’Rourke,

Molecular Therapy — Oncolytics · 2022 · 39 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

. Overall, we demonstrated the potential of combining the IAP antagonist birinapant with CAR T cells as a novel and feasible approach to overcoming tumor antigen heterogeneity and enhancing CAR T cell therapy for GBM.

References

35

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp, Michael Kalos, David M. Barrett et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text

, , +16

X-linked IAP is a direct inhibitor of cell-death proteases

Quinn L. Deveraux, Ryōsuke Takahashi, Guy S. Salvesen et al. · Nature · 1997 · 1.9K citations · Full text

, , +12

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

, , +17

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai et al. · Science Translational Medicine · 2017 · 1.8K citations · Full text

, , +17

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

Eugene Varfolomeev, John W. Blankenship, Sarah M. Wayson et al. · Cell · 2007 · 1.2K citations · Full text

, , +16